$EYES News
Last published 4y ago
- 4y agoEYESVANIVivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)Business WireVivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ:VANI) (the "Company" or "Vivani") announced that trading of the Company's common stock on The Nasdaq Capital Market under the symbol "VANI" will commence today. Vivani is the combinat
- 4y agoEYESEYESWVANISecond Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.Business WireVivani will be traded under the new ticker (NASDAQ:VANI) Second Sight Medical Products, Inc.(NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of usefu
- 4y agoEYESSecond Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual MeetingBusiness WireSecond Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of usefu
- 4y agoEYESSecond Sight Medical Products Announces Year Four NIH Funding of its Orion StudyBusiness WireGrant proceeds support an ongoing early feasibility study of Orion Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prostheses that are intended to create an artificial for
- 4y agoEYESNano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®Business WireSecond Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. ("
- 4y agoBDSIEYESGIIXZWSMoore Kuehn Encourages BDSI, ZWS, EYES, and GIIX Investors to Contact Law FirmPR NewswireNEW YORK, Feb. 15, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sha
- 4y agoEYESSecond Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant CompanyBusiness WireNano Precision Medical's lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes Second Sight will issue 134M shares to acquire full ownership of Nano Precision Medical. Second Sight sh
- 5y agoEYESSecond Sight Medical Products Announces a New NIH Grant Supplement for Its Orion StudyBusiness WireGrant proceeds support a patient preference information study of Orion subjects Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an
- 5y agoEYESSecond Sight Medical Products Announces Closing of Public OfferingBusiness WireSecond Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or the "Company"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing
- 5y agoEYESSecond Sight Medical Products Announces Pricing of Public OfferingBusiness WireSecond Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or the "Company"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing
- 5y agoEYESSecond Sight Medical Products Announces Proposed Public Offering of Common StockBusiness WireSecond Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or the "Company") a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it inte
- 5y agoEYESSecond Sight Medical Products Announces Results of its 2021 Annual MeetingBusiness WireSecond Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of
- 5y agoEYESSecond Sight Medical Products Announces Year Three NIH Funding of Its Orion StudyBusiness WireGrant proceeds support ongoing early feasibility study of Orion Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form
- 5y agoARRYCCLEYESINTC+1Thinking about buying stock in Second Sight Medical, Plug Power, Array Technologies, Carnival Corp, or Intel Corp?PR NewswireNEW YORK, May 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EYES, PLUG, ARRY, CCL, and INTC. To
- 5y agoEYESSecond Sight Medical Products Announces Two-Year Results of its Orion StudyBusiness WireSecond Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announce
- 5y agoEYESSecond Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of DirectorsBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company’s Board of Directors has appointed two new members, Dr. Dean Baker and Ms. Alexandra Larson. Dr. ...
- 5y agoEYESSecond Sight Medical Products Names Scott Dunbar Acting CEOBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company’s Board of Directors has named Scott Dunbar to replace Matthew Pfeffer as acting Chief Executive ...
- 5y agoEYESSecond Sight Medical Products Announces Closing of $27.9 Million Private Placement of Common StockBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has closed its previously announced private placement, which resulted in gross proceeds to Second Sight of ...
- 5y agoEYESSecond Sight Medical Products Announces $27.9 Million Private Placement of Common StockBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES), (the "Company" or "Second Sight"), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has entered into definitive securities purchase agreements with accredited investors for a private placem ...
- 5y agoAMCGMEOPGNXELA+3Meme Stock Revival Drives Millions of Trades in Tiny StocksBloombergMore shares of Second Sight Medical Products Inc. and INVO BioScience Inc. traded on the Nasdaq Tuesday then than those of tech bellwether Apple Inc.
- 5y agoEYESContinuation of the business combination project between Pixium Vision et Second Sight Medical ProductsGlobeNewswireParis, France, March 09, 2021 – Pixium Vision (Euronext Growth Paris - FR0011950641) announces that the business combination with Second Sight Medical Products, Inc. (« Second Sight ») (Nasdaq:...
- 5y agoEYESSecond Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis SystemBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced U.S. Food and Drug Administration (FDA) has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video proces ...
- 5y agoEYESNew patent granted for: Uses for Eye Tracking in a Visual ProsthesisUS Patent Applications (USPTO)
- 5y agoEYESPixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration marketGlobeNewswirePixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market Aims to create a global leader with potential to treat nearly...
- 6y agoEYESSecond Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLABusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) at UCLA Medical Center (“UCLA”). The st ...
- 6y agoEYESSecond Sight Medical Products Inc. Announces Closing of Public Offering of Common StockBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it closed its previously announced underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per shar ...
- 6y agoEYESSecond Sight Medical Products Announces Pricing of Public Offering of Common StockBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of an underwritten public offering of 7,500,000 shares of common stock, no par value (the “Common Stock”) at an offering price of $ ...
- 6y agoEYESNew patent granted for: Visual Prosthetic Apparatus for Retinal StimulationUS Patent Applications (USPTO)
- 6y agoEYESSecond Sight Announces Employee Layoffs, Intent to Wind Down Operations and Appointment of Matthew Pfeffer as Acting CEOBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced that in response to the impact of the global COVID-19 pandemic on its ability to secure financing, the Company wil ...
- 6y agoEYESSecond Sight Reports Fourth Quarter and Full Year 2019 Financial ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three months and full year ended December 31, 2019.
- 6y agoEYESSecond Sight to Discuss Fourth Quarter and Year-End 2019 Financial Results on March 19, 2020 Conference CallBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, will release its 2019 fourth quarter and year-end financial results on Thursday, March 19, 2020, after the close of the U.S. ...
- 6y agoRMEDEYESRa Medical Systems Appoints Medtech Executive Will McGuire as CEO and DirectorBusiness WireCARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the appointment of Will McGuire as Chief Executive Officer and a member of the company’s Board of Directors, effective March 30, 2020. Andrew Jackson, who has served as Interim CEO since August ...
- 6y agoEYESSecond Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEOBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the departure of Will McGuire, President and Chief Executive Officer (“CEO”), effective March 27, 2020, to p ...
- 6y agoEYESSecond Sight Medical Products, Inc's (EYES) CEO Will McGuire on Q3 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoEYESSecond Sight Reports Third Quarter 2019 Financial ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three and nine months ended September 30, 2019.
- 7y agoEYESSecond Sight to Discuss Third Quarter 2019 Financial Results on November 14, 2019 Conference CallBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will release its financial results for the third quarter of 2019 on Thursday, November 14, 2019, after the close of the U.S. financial markets.
- 7y agoEYESSecond Sight to Present at September Investor ConferencesBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics today announced that Will McGuire, President and Chief Executive Officer, and John Blake, Chief Financial Officer, are scheduled to present at three upcoming conferences as follows:
- 7y agoEYESSecond Sight Reports Second Quarter 2019 Financial ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three- and six-months ended June 30, 2019.
- 7y agoEYESSecond Sight to Discuss Second Quarter 2019 Financial Results on August 6, 2019 Conference CallBusiness WireLOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, will release its financial results for the second quarter of 2019 on Tuesday, August 6, 2019, after the close of the U.S. financial markets.
- 7y agoEYESResearchers Present Latest Positive Results of Second Sight’s Orion Visual Cortical Prosthesis Feasibility StudyBusiness WireLOS ANGELES & NEW YORK--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, announced that 12-month results from the Company’s Early Feasibility Study of the Orion® Visual Cortical Prosthesis System ...
- 7y agoEYESSecond Sight Medical Products, Inc. (EYES) CEO Will McGuire on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoEYESSecond Sight Medical Products' (EYES) CEO Will McGuire on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts